|
1
|
Lheureux S, Gourley C, Vergote I and Oza
AM: Epithelial ovarian cancer. Lancet. 393:1240–1253. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Chen W, Zheng R, Baade PD, Zhang S, Zeng
H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China,
2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Marcus CS, Maxwell GL, Darcy KM, Hamilton
CA and McGuire WP: Current approaches and challenges in managing
and monitoring treatment response in ovarian cancer. J Cancer.
5:25–30. 2014. View
Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ledermann JA, Raja FA, Fotopoulou C,
Gonzalez-Martin A, Colombo N and Sessa C; ESMO Guidelines Working
Group, : Newly diagnosed and relapsed epithelial ovarian carcinoma:
ESMO Clinical Practice Guidelines for diagnosis, treatment and
follow-up. Ann Oncol. 24:vi24–vi32. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Asgari Z, Rouholamin S, Hosseini R,
Sepidarkish M, Hafizi L and Javaheri A: Comparing ovarian reserve
after laparoscopic excision of endometriotic cysts and hemostasis
achieved either by bipolar coagulation or suturing: A randomized
clinical trial. Arch Gynecol Obstet. 293:1015–1022. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Qin L, Qiu H, Zhang M, Zhang F, Yang H,
Yang L, Jia L, Qin K, Jia L, Dou X, et al: Soluble CD40 ligands
sensitize the epithelial ovarian cancer cells to cisplatin
treatment. Biomed Pharmacother. 79:166–175. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Yang F, Gao B, Chen W, Du E, Liang Y, Hu X
and Yang X: Expression of resistance gene and prognosis of
chemotherapy in primary epithelial ovarian cancer. Medicine
(Baltimore). 97:e123642018. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Matei D, Fang F, Shen C, Schilder J,
Arnold A, Zeng Y, Berry WA, Huang T and Nephew KP: Epigenetic
resensitization to platinum in ovarian cancer. Cancer Res.
72:2197–2205. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yin F, Liu X, Li D, Wang Q, Zhang W and Li
L: Tumor suppressor genes associated with drug resistance in
ovarian cancer (review). Oncol Rep. 30:3–10. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Chaudhry P, Srinivasan R and Patel FD:
Utility of gene promoter methylation in prediction of response to
platinum-based chemotherapy in epithelial ovarian cancer (EOC).
Cancer Invest. 27:877–884. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Yang F, Gao B, Li R, Li W, Chen W, Yu Z
and Zhang J: Expression levels of resistant genes affect cervical
cancer prognosis. Mol Med Rep. 15:2802–2806. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Koh I, Hinoi T, Sentani K, Hirata E,
Nosaka S, Niitsu H, Miguchi M, Adachi T, Yasui W, Ohdan H and Kudo
Y: Regulation of multidrug resistance 1 expression by CDX2 in
ovarian mucinous adenocarcinoma. Cancer Med. 5:1546–1555. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Balch C, Huang TH, Brown R and Nephew KP:
The epigenetics of ovarian cancer drug resistance and
resensitization. Am J Obstet Gynecol. 191:1552–1572. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lu C, Shan Z, Li C and Yang L: MiR-129
regulates cisplatin-resistance in human gastric cancer cells by
targeting P-gp. Biomed Pharmacother. 86:450–456. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Javadi S, Ganeshan DM, Qayyum A, Iyer RB
and Bhosale P: Ovarian cancer, the revised FIGO staging system and
the role of imaging. AJR Am J Roentgenol. 206:1351–1360. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kurman RJ, Carcangiu ML, Herrington CS and
Young RH: WHO Classification of Tumours of Female Reproductive
Organs. (4th). International Agency for Research on Cancer.
3072014.
|
|
17
|
Prat J; FIGO Committee on Gynecologic
Oncology, : Staging classification for cancer of the ovary,
fallopian tube, and peritoneum. Int J Gynaecol Obstet. 124:1–5.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Herman JG, Graff JR, Myöhänen S, Nelkin BD
and Baylin SB: Methylation-specific PCR: A novel PCR assay for
methylation status of CpG islands. Proc Natl Acad Sci USA.
93:9821–9826. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Yuan Z, Shi X, Qiu Y, Jia T, Yuan X, Zou
Y, Liu C, Yu H, Yuan Y, He X, et al: Reversal of P-gp-mediated
multidrug resistance in colon cancer by cinobufagin. Oncol Rep.
37:1815–1825. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Stewart DJ: Tumor and host factors that
may limit efficacy of chemotherapy in non-small cell and small cell
lung cancer. Crit Rev Oncol Hematol. 75:173–264. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhang KG, Qin CY, Wang HQ, Wang JX and
Wang QM: The effect of TRAIL on the expression of multidrug
resistant genes MDR1, LRP and GST-π in drug-resistant gastric
cancer cell SGC7901/VCR. Hepatogastroenterology. 59:2672–2676.
2012.PubMed/NCBI
|
|
23
|
Wei H, Lu W, Li M, Zhang Q and Lu S:
Concomitance of P-gp/LRP expression with EGFR mutations in exons 19
and 21 in non-small cell lung cancers. Yonsei Med J. 57:50–57.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Jiao JW and Wen F: Tanshinone IIA acts via
p38 MAPK to induce apoptosis and the down-regulation of ERCC1 and
lung-resistance protein in cisplatin-resistant ovarian cancer
cells. Oncol Rep. 25:781–788. 2011.PubMed/NCBI
|
|
25
|
Zhan L, Zhang B, Tan Y, Yang C, Huang C,
Wu Q, Zhang Y, Chen X, Zhou M and Shu A: Quantitative assessment of
the relationship between RASSF1A gene promoter methylation and
bladder cancer (PRISMA). Medicine (Baltimore). 96:e60972017.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Shou F, Xu F, Li G, Zhao Z, Mao Y, Yang F,
Wang H and Guo H: RASSF1A promoter methylation is associated with
increased risk of thyroid cancer: A meta-analysis. Onco Targets
Ther. 10:247–257. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Vos MD, Martinez A, Elam C, Dallol A,
Taylor BJ, Latif F and Clark GJ: A role for the RASSF1A tumor
suppressor in the regulation of tubulin polymerization and genomic
stability. Cancer Res. 64:4244–4250. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kassler S, Donninger H, Birrer MJ and
Clark GJ: RASSF1A and the taxol response in ovarian cancer. Mol
Biol Int. 2012:2632672012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Choi YL, Kang SY, Shin YK, Choi JS, Kim
SH, Lee SJ, Bae DS and Ahn G: Aberrant hypermethylation of RASSF1A
promoter in ovarian borderline tumors and carcinomas. Virchows
Arch. 448:331–336. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Pronina IV, Loginov VI, Kholdyrev DS,
Kazubskaia TP and Braga ÉA: Alterations of expression level of
RASSFIA gene in primary epithelial tumors of various locations. Mol
Biol (Mosk). 46:260–268. 2012.(In Russian). View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Balch C, Yan P, Craft T, Young S, Skalnik
DG, Huang TH and Nephew KP: Antimitogenic and chemosensitizing
effects of the methylation inhibitor zebularine in ovarian cancer.
Mol Cancer Ther. 4:1505–1514. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Hou XL, Takahashi K, Tanaka K, Tougou K,
Qiu F, Komatsu K, Takahashi K and Azuma J: Curcuma drugs and
curcumin regulate the expression and function of P-gp in Caco-2
cells in completely opposite ways. Int J Pharm. 358:224–229. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Cao SQ, Li P, Yin TY and Yang SL: Curcumin
reverses multi-drugresistance of human hepatocellular carcinoma
bel7402/5-FU cells. World Chin J Digestol. 20:135–139. 2012.
|
|
34
|
Wang N, Zhang H, Yao Q, Wang Y, Dai S and
Yang X: TGFBI promoter hypermethylation correlating with paclitaxel
chemoresistance in ovarian cancer. J Exp Clin Cancer Res. 31:62012.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Chiang YC, Chang MC, Chen PJ, Wu MM, Hsieh
CY, Cheng WF and Chen CA: Epigenetic silencing of BLU through
interfering apoptosis results in chemoresistance and poor prognosis
of ovarian serous carcinoma patients. Endocr Relat Cancer.
20:213–227. 2013. View Article : Google Scholar : PubMed/NCBI
|
